Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands

Stephané Roze,1 Jayne Smith-Palmer,2 Simona de Portu,3 Alexis Delbaere,3 Bonnie de Brouwer,4 Harold W de Valk5 1HEVA HEOR, Lyon, France; 2Ossian Health Economics and Communications, Basel, Switzerland; 3Medtronic International Trading Sàrl, Tolochenaz, Switzerland; 4Medtronic Trading NL, Heerlen, the Netherlands; 5Leiden University Medical Center, Leiden, the Netherlands Aim: The aim of this study was to perform a cost-effectiveness analysis to establish the cost-effectiveness of sensor-augmented pump therapy (SAP) with automated insulin suspension vs continuous subcutaneous insulin infusion (... Mehr ...

Verfasser: Roze S
Smith-Palmer J
de Portu S
Dalbaere A
de Brouwer B
de Valk HW
Dokumenttyp: Artikel
Erscheinungsdatum: 2019
Reihe/Periodikum: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 73-82 (2019)
Verlag/Hrsg.: Dove Medical Press
Schlagwörter: Cost / cost-effectiveness / type 1 diabetes / the Netherlands / sensor-augmented insulin pump therapy / Medicine (General) / R5-920 / Therapeutics. Pharmacology / RM1-950
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27579812
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doaj.org/article/324f35e4bfc845288b9717b7d6bf9e74